J-GLOBAL ID:201401001067568642   Update date: Jul. 01, 2023

Harada Hiroshi

ハラダ ヒロシ | Harada Hiroshi
Affiliation and department:
Research field  (6): Molecular biology ,  Cell biology ,  Pathobiochemistry ,  Radiology ,  Genomics ,  Tumor biology
Research theme for competitive and other funds  (30):
  • 2023 - 2026 放射線抵抗性の腫瘍内低酸素分画をモニターする血中バイオマーカーの開発
  • 2021 - 2026 Assessment of the relationship between the dynamics of tumor hypoxia areas and hypoxia inducible factor in radiotherapy for pancreatic cancer
  • 2022 - 2025 Plasma biomarkers for "early detection" and "prognosis prediction" of cancer using intratumoral hypoxia as an indicator
  • 2020 - 2025 Formation of an international research center for integrated radiation science targeting complex systems in living organisms
  • 2021 - 2024 がん個別化放射線治療法の確立に向けたTR研究
Show all
Papers (153):
  • Takata M, Harada H. AT workshop 2023 -A platform for discussing cutting-edge science in DNA damage signaling, repair, and human disorders-. Genes to Cells. 2023
  • Chow CCT, Kobayashi M, Kambe G, *Harada H. ZBTB2 is recruited to a specific subset of HIF-1 target loci to facilitate full gene expression under hypoxia. Journal of Molecular Biology. 2023. in press
  • Jin S, Jin B, Ishikawa T, Ninagawa S, Okada T, Koyasu S, Harada H, Mori K. Loss of ATF6α in a Human Carcinoma Cell Line Is Compensated not by Its Paralogue ATF6β but by Sustained Activation of the IRE1 and PERK Arms for Tumor Growth in Nude Mice. Molecular Biology of the Cell. 2023. 34. 3. ar20
  • Koyasu S, Horita S, Saito K, Kobayashi M, Ishikita H, Chow CCT, Kambe G, Nishikawa S, Menjyu T, Morinibu A, et al. ZBTB2 links p53-deficiency to HIF-1-mediated hypoxia signaling for cancer aggressiveness. EMBO Rep. 2023. 24. 1. e54042
  • Radiation-induced cell death and resultant tissue injury. 2022. 283. 5. 511-516
MISC (23):
Patents (9):
  • 低酸素バイオマーカー及びその利用
  • 低酸素バイオマーカー及びその利用
  • がんを治療するための医薬組成物
  • がんを治療するための医薬組成物
  • 新規抗腫瘍剤及び新規抗腫瘍剤のスクリーニング方法
Books (3):
  • Molecularly based Chemoradiotherapy and High-Precision Radiotherapy. Tan D, Lynch H (eds).
    Lippincott Williams & Milkins. 2012
  • Protein Transduction Domain-mediated Delivery of Anti-cancer Drugs and Proteins. Lu Y and Mahato RI (eds). Pharmaceutical Perspectives of Cancer Therapeutics.
    Springer 2009
  • Combination of Antimetabolites and Ionizing Radiation. Medical Radiology: Radiation Oncology, Multimodal Concepts for Integration of Cytotoxic Drugs.
    Springer 2006
Lectures and oral presentations  (150):
  • Tumor hypoxia as a predictor for radiation therapy
    (Annual Meeting of European Society for Radiotherapy and Oncology 2023 (ESTRO2023) 2023)
  • 変異KRAS分子標的薬と放射線治療の併用効果に対する 腫瘍内酸素環境の影響の考察
    (日本癌学会シンポジウム・KRAS分子標的薬の開発 2023)
  • 腫瘍低酸素と放射線抵抗性
    (第13回日本放射線腫瘍学会・放射線生物学セミナー 2023)
  • Hypoxic tumor cells: their dynamics during tumor growth and involvement in recurrence after radiation therapy.
    (Sussex-Japan Genome Stability Meeting 2023)
  • Radioresistance of Hypoxic Tumor Cells.
    (The 13th International Symposium on the DNA Damage Response & Human Disease 2022 (isDDRHD-2022) 2022)
Professional career (1):
  • 博士(理学) (名古屋大学)
Awards (12):
  • 2023/06 - Osaka Neuclear Science Association ONSA Award
  • 2022/12 - Japanese Society for Radiation Oncoglogy Abe Award
  • 2018/11 - Journal of Radiation Research JRR Terasima Award Hypoxia-inducible factor 1-mediated characteristic features of cancer cells for tumor radioresistance
  • 2014/10 - 日本放射線腫瘍学会 第12回優秀教育講演賞 放射線腫瘍学における"がん幹細胞"と"低酸素"
  • 2013/05 - 公益財団法人 放射線影響協会 放射線影響研究奨励賞 細胞の低酸素応答が放射線感受性に及ぼす影響の解析
Show all
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page